Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Operating Income Loss of -$104.02 million for the year ending 2025.
- ALX ONCOLOGY HOLDINGS INC showed an increase of +27.0% in Operating Income Loss from 2024 to 2025.
- This data is from ALX ONCOLOGY HOLDINGS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), ALX ONCOLOGY HOLDINGS INC's Operating Income Loss has declined by 660.2%.
- Historical annual values: Fiscal year 2025: -$104.02 million | Fiscal year 2024: -$142.47 million | Fiscal year 2023: -$170.28 million | Fiscal year 2022: -$127.44 million | Fiscal year 2021: -$83.56 million | Fiscal year 2020: -$43.66 million | Fiscal year 2019: -$19.18 million | Fiscal year 2018: -$13.68 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: